A61K 39/292
Serum hepatitis virus, hepatitis b virus
Official title: {Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen}
A61K39/292 (Serum hepatitis virus, hepatitis b virus) appears on 370 US grants and 633 published applications in this corpus.
Search patents in A61K- Granted patents
- 370
- Published applications
- 633
- Assignees
- 357
- Inventors
- 1,261
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1980 | 2 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 0 | 0 |
| 1987 | 4 | 0 |
| 1988 | 2 | 0 |
| 1989 | 1 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 3 | 0 |
| 1998 | 4 | 0 |
| 1999 | 3 | 0 |
| 2000 | 4 | 0 |
| 2001 | 4 | 1 |
| 2002 | 12 | 18 |
| 2003 | 4 | 26 |
| 2004 | 6 | 26 |
| 2005 | 8 | 31 |
| 2006 | 6 | 21 |
| 2007 | 10 | 17 |
| 2008 | 14 | 24 |
| 2009 | 12 | 26 |
| 2010 | 9 | 31 |
| 2011 | 6 | 21 |
| 2012 | 10 | 20 |
| 2013 | 10 | 24 |
| 2014 | 18 | 40 |
| 2015 | 12 | 26 |
| 2016 | 27 | 32 |
| 2017 | 16 | 40 |
| 2018 | 29 | 16 |
| 2019 | 22 | 27 |
| 2020 | 22 | 26 |
| 2021 | 13 | 25 |
| 2022 | 17 | 32 |
| 2023 | 15 | 24 |
| 2024 | 10 | 24 |
| 2025 | 21 | 18 |
| 2026 | 5 | 17 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment of diseases related to hepatitis B virus18 Aug 2026US 12,709,634 B2Erasmus University Medical Center Rotterdam
- Pharmaceutical composition and use thereof12 May 2026US 12,622,962 B2Grand Theravac Life Sciences (Nanjing) Co., Ltd.
- Adenoviral vectors encoding hepatitis B viral antigens fused to herpes virus glycoprotein D and methods of using the same21 Apr 2026US 12,605,444 B2The Wistar Institute
- Transient expression of biologic materials17 Mar 2026US 12,576,041 B1
- HBV vaccine13 Jan 2026US 12,521,431 B2Oxford University Innovation Limited
- Inhaled adenovirus vector vaccine, preparation method therefor and use thereof8 Oct 2026US 2026/0306605 A1Cansino Biologics Inc.
- Tumor neoantigen vaccine system specifically marking heterologous protein, and use thereof8 Oct 2026US 2026/0306620 A1China Pharmaceutical University
- Biological response modifiers for the treatment of subjects with underperforming immune systems and compositions thereof24 Sep 2026US 2026/0284186 A1Center for Genetic Engineering and Biotechnology (Cigb)
- Polysaccharide adjuvants for use in protein-based or rna-based vaccines24 Sep 2026US 2026/0284187 A1Children's Medical Center Corporation
- Oligonucleotides for use in modulating immune responses against hepatitis b viral infection3 Sep 2026US 2026/0256907 A1Ausperbio Therapeutics Inc.
Most cited
By later US patents
- Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant395US 6,406,705 B1Coley Pharmaceutical GmbH · 2002
- Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix365US 6,309,669 B1The United States of America as represented by the Secretary of the Army · 2001
- Vectors and methods for immunization or therapeutic protocols285US 6,339,068 B12002
- Method for immunizing animals with synthetically modified vaccinia virus240US 4,722,848 AHealth Research, Inc. · 1988
- Compositions and methods for delivery of genetic material184US 5,739,118 AApollon Inc. · 1998